The results of all these studies suggested that the combination of the PD-1/PD-L1 inhibitor and chemotherapy is unlikely to be a cost-effective option for patients with advanced NSCLC compared to chemotherapy alone, consistent with our results. This evidence concerns the gene CD274 and non-small cell lung carcinoma.